{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:35:57Z","timestamp":1790861757207,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/j.nbd.2003.10.003","type":"journal-article","created":{"date-parts":[[2003,12,22]],"date-time":"2003-12-22T22:58:37Z","timestamp":1072133917000},"page":"160-170","source":"Crossref","is-referenced-by-count":77,"title":["Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication"],"prefix":"10.1016","volume":"15","author":[{"given":"Carsten","family":"Buhmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6nke","family":"Arlt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatol","family":"Kontush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"M\u00f6ller-Bertram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinje","family":"Sperber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Oechsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joerg","family":"Stuerenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Beisiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2003.10.003_BIB1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/mds.870100507","article-title":"No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease","volume":"10","author":"Ahlskog","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2003.10.003_BIB2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1212\/WNL.46.3.796","article-title":"Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease","volume":"46","author":"Ahlskog","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2003.10.003_BIB3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/10715760000300111","article-title":"Time-course of oxidation of lipids in human cerebrospinal fluid in vitro","volume":"32","author":"Arlt","year":"2000","journal-title":"Free Radical Res."},{"key":"10.1016\/j.nbd.2003.10.003_BIB4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/nbdi.2002.0496","article-title":"Increased lipid peroxidation in cerebrospinal fluid and plasma from patients with Creutzfeldt-Jakob disease","volume":"10","author":"Arlt","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2003.10.003_BIB5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1471-4159.1995.64020825.x","article-title":"l-Dopa cytotoxicity to PC12 cells in culture is via its autoxidation","volume":"64","author":"Basma","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2003.10.003_BIB6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s11745-999-0478-1","article-title":"Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo","volume":"34","author":"Bassett","year":"1999","journal-title":"Lipids"},{"key":"10.1016\/j.nbd.2003.10.003_BIB7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1212\/WNL.38.9.1410","article-title":"Does levodopa aggravate Parkinson's disease?","volume":"38","author":"Blin","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2003.10.003_BIB8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0005-2760(94)00232-N","article-title":"Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid","volume":"1255","author":"Borghini","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2003.10.003_BIB9","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1046\/j.1471-4159.2000.741229.x","article-title":"l-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion","volume":"74","author":"Camp","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2003.10.003_BIB10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0006-8993(96)00729-9","article-title":"Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease","volume":"737","author":"Castellani","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2003.10.003_BIB13","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1471-4159.1989.tb07264.x","article-title":"Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease","volume":"52","author":"Dexter","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2003.10.003_BIB11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.1989.tb09133.x","article-title":"Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease","volume":"52","author":"Dexter","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2003.10.003_BIB12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/mds.870090115","article-title":"Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study","volume":"9","author":"Dexter","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2003.10.003_BIB14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00001756-199703030-00031","article-title":"Absence of neurotoxicity of chronic l-DOPA in 6-hydroxydopamine-lesioned rats","volume":"8","author":"Dziewczapolski","year":"1997","journal-title":"NeuroReport"},{"key":"10.1016\/j.nbd.2003.10.003_BIB15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/10715768909073429","article-title":"Continuous monitoring of in vitro oxidation of human low density lipoprotein","volume":"6","author":"Esterbauer","year":"1989","journal-title":"Free Radical Res. Commun."},{"key":"10.1016\/j.nbd.2003.10.003_BIB16","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1212\/WNL.47.6_Suppl_3.184S","article-title":"Is levodopa toxic?","volume":"47","author":"Fahn","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2003.10.003_BIB17","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ana.410320616","article-title":"The oxidant stress hypothesis in Parkinson's disease: evidence supporting it","volume":"32","author":"Fahn","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0022-510X(93)90240-Y","article-title":"Serum levels of ascorbic acid (vitamin C) in patients with Parkinson's disease","volume":"118","author":"Fernandez-Calle","year":"1993","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.nbd.2003.10.003_BIB19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0076-6879(99)99034-1","article-title":"High-performance liquid chromatography-coulometric electrochemical detection of ubiquinol 10, ubiquinone 10, carotenoids, and tocopherols in neonatal plasma","volume":"299","author":"Finckh","year":"1999","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB20","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0022-2275(20)35354-2","article-title":"Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and -independent oxidation","volume":"34","author":"Frei","year":"1993","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.nbd.2003.10.003_BIB21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02224396","article-title":"A case control study of CSF copper, iron and manganese in Parkinson disease","volume":"13","author":"Gazzaniga","year":"1992","journal-title":"Ital. J. Neurol. Sci."},{"key":"10.1016\/j.nbd.2003.10.003_BIB22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease","volume":"51","author":"Gibb","year":"1988","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"key":"10.1016\/j.nbd.2003.10.003_BIB23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s007020200052","article-title":"Pergolide protects dopaminergic neurons in primary culture under stress conditions","volume":"109","author":"Gille","year":"2002","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nbd.2003.10.003_BIB24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00041433-199710000-00005","article-title":"Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis","volume":"8","author":"Heinecke","year":"1997","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2003.10.003_BIB26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0006-8993(99)01688-1","article-title":"Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist","volume":"838","author":"Iida","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2003.10.003_BIB27","first-page":"141","article-title":"Oxidative stress indicators are elevated in de novo Parkinson's disease patients","volume":"14","author":"Ilic","year":"1999","journal-title":"Funct. Neurology"},{"key":"10.1016\/j.nbd.2003.10.003_BIB29","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1212\/WNL.47.6_Suppl_3.161S","article-title":"Oxidative stress and the pathogenesis of Parkinson's disease","volume":"47","author":"Jenner","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2003.10.003_BIB28","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1002\/ana.410320714","article-title":"Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group","volume":"32","author":"Jenner","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0304-3940(93)90653-3","article-title":"Serum levels of beta-carotene and other carotenoids in Parkinson's disease","volume":"157","author":"Jimenez-Jimenez","year":"1993","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2003.10.003_BIB30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s007020050073","article-title":"Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease","volume":"105","author":"Jimenez-Jimenez","year":"1998","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nbd.2003.10.003_BIB31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s007020050015","article-title":"Serum levels of coenzyme Q10 in patients with Parkinson's disease","volume":"107","author":"Jimenez-Jimenez","year":"2000","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nbd.2003.10.003_BIB33","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1046\/j.1471-4159.2000.0742296.x","article-title":"Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells","volume":"74","author":"Jones","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2003.10.003_BIB34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF02454194","article-title":"Serum antioxidant enzyme activity in Parkinson's disease","volume":"110","author":"Kalra","year":"1992","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.nbd.2003.10.003_BIB35","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/pgmj.68.802.634","article-title":"Concentrations of vitamins A, C and E in elderly patients with Parkinson's disease","volume":"68","author":"King","year":"1992","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.nbd.2003.10.003_BIB36","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0022-2275(20)31605-9","article-title":"Characterization of four lipoprotein classes in human cerebrospinal fluid","volume":"42","author":"Koch","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.nbd.2003.10.003_BIB37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0076-6879(99)99007-9","article-title":"Measurement of oxidizability of blood plasma","volume":"299","author":"Kontush","year":"1999","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10715769609088009","article-title":"How different constituents of low density lipoprotein determine its oxidizability by copper: a correlational approach","volume":"24","author":"Kontush","year":"1996","journal-title":"Free Radical Res."},{"key":"10.1016\/j.nbd.2003.10.003_BIB39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0021-9150(96)06021-2","article-title":"Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia","volume":"129","author":"Kontush","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nbd.2003.10.003_BIB40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0014-5793(94)00903-1","article-title":"Iron released from transferrin at acidic pH can catalyse the oxidation of low density lipoprotein","volume":"352","author":"Lamb","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.nbd.2003.10.003_BIB41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/neur.1995.0018","article-title":"Lipid peroxidation in brain: interactions of l-DOPA\/dopamine with ascorbate and iron","volume":"4","author":"Li","year":"1995","journal-title":"Neurodegeneration"},{"key":"10.1016\/j.nbd.2003.10.003_BIB42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00002093-199408030-00005","article-title":"Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease","volume":"8","author":"Loeffler","year":"1994","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.nbd.2003.10.003_BIB43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0014-2999(02)02683-3","article-title":"Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress","volume":"457","author":"Lombardi","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0891-5849(95)02207-4","article-title":"The effect of ascorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity","volume":"21","author":"Lonnrot","year":"1996","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.nbd.2003.10.003_BIB45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s702-002-8236-2","article-title":"Chronic high dose l-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys","volume":"109","author":"Lyras","year":"2002","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nbd.2003.10.003_BIB46","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","article-title":"Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression","volume":"287","author":"Marek","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.nbd.2003.10.003_BIB47","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0891-5849(99)00075-1","article-title":"Peripheral markers of oxidative stress in Parkinson's disease. The role of l-DOPA","volume":"27","author":"Martignoni","year":"1999","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.nbd.2003.10.003_BIB48","series-title":"Biomedical an Clinical Aspects of Coenzyme Q","first-page":"159","article-title":"Serum coenzyme Q10 level in Parkinson syndrome","author":"Matsubara","year":"1991"},{"key":"10.1016\/j.nbd.2003.10.003_BIB49","first-page":"12","article-title":"Serum pro-oxidant and antioxidant factors and risk of Parkinson's disease: population study","volume":"29","author":"Molina-Arjona","year":"1999","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB50","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/BF01294729","article-title":"Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease","volume":"104","author":"Molina","year":"1997","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nbd.2003.10.003_BIB51","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/S0022-2275(20)33324-1","article-title":"Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins","volume":"39","author":"Montine","year":"1998","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.nbd.2003.10.003_BIB52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0076-6879(94)34094-3","article-title":"Measurement of antioxidants in human blood plasma","volume":"234","author":"Motchnik","year":"1994","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB53","doi-asserted-by":"crossref","first-page":"14773","DOI":"10.1074\/jbc.271.25.14773","article-title":"Ceruloplasmin enhances smooth muscle","volume":"271","author":"Mukhopadhyay","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2003.10.003_BIB54","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1002\/ana.410440713","article-title":"Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress?","volume":"44","author":"Munch","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB55","first-page":"295","article-title":"Lipid peroxidation and tissue damage","volume":"13","author":"Mylonas","year":"1999","journal-title":"In vivo"},{"key":"10.1016\/j.nbd.2003.10.003_BIB57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-8993(95)00988-7","article-title":"Acute l-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice","volume":"701","author":"Naudin","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2003.10.003_BIB58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(87)90827-0","article-title":"Raised cerebrospinal-fluid copper concentration in Parkinson's disease","volume":"2","author":"Pall","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.nbd.2003.10.003_BIB59","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1471-4159.1984.tb12834.x","article-title":"Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of l-DOPA and carbidopa chronically","volume":"43","author":"Perry","year":"1984","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2003.10.003_BIB60","doi-asserted-by":"crossref","first-page":"14352","DOI":"10.1016\/S0021-9258(18)47945-8","article-title":"Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain","volume":"262","author":"Pitas","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2003.10.003_BIB61","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/mds.870120503","article-title":"Is levodopa toxic to human substantia nigra?","volume":"12","author":"Rajput","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2003.10.003_BIB62","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10715769309056514","article-title":"Analysis of lipoprotein diene formation in human serum exposed to copper","volume":"19","author":"Regnstrom","year":"1993","journal-title":"Free Radical Res. Commun."},{"key":"10.1016\/j.nbd.2003.10.003_BIB63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0166-2236(99)01543-X","article-title":"Ascorbate regulation and its neuroprotective role in the brain","volume":"23","author":"Rice","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.nbd.2003.10.003_BIB64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","article-title":"Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains","volume":"52","author":"Riederer","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2003.10.003_BIB66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0891-5849(99)00247-6","article-title":"Increased lipoprotein oxidation in Alzheimer's disease","volume":"28","author":"Schippling","year":"2000","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.nbd.2003.10.003_BIB67","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s007020170003","article-title":"Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients","volume":"108","author":"Serra","year":"2001","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nbd.2003.10.003_BIB70","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF01244786","article-title":"Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain","volume":"74","author":"Sofic","year":"1988","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nbd.2003.10.003_BIB69","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1471-4159.1991.tb02017.x","article-title":"Selective increase of iron in substantia nigra zona compacta of parkinsonian brains","volume":"56","author":"Sofic","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2003.10.003_BIB68","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0304-3940(92)90355-B","article-title":"Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease","volume":"142","author":"Sofic","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2003.10.003_BIB71","first-page":"73","article-title":"Model for transport in the central nervous system","volume":"232","author":"Spector","year":"1977","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0009-3084(97)00092-3","article-title":"How different constituents of human plasma and low density lipoprotein determine plasma oxidizability by copper","volume":"91","author":"Spranger","year":"1998","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.nbd.2003.10.003_BIB73","first-page":"915","article-title":"Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity","volume":"320","author":"Steinberg","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2003.10.003_BIB74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0304-4165(93)90090-U","article-title":"Extracellular reduction of ubiquinone-1 and-10 by human Hep G2 and blood cells","volume":"1158","author":"Stocker","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2003.10.003_BIB76","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0022-510X(91)90046-A","article-title":"Dopa and dopamine cause cultured neuronal death in the presence of iron","volume":"101","author":"Tanaka","year":"1991","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.nbd.2003.10.003_BIB75","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1007672414239","article-title":"Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist","volume":"26","author":"Tanaka","year":"2001","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.nbd.2003.10.003_BIB77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1179\/016164102101199729","article-title":"Inhibition of human LDL oxidation by the neuroprotective drug l-deprenyl","volume":"24","author":"Thomas","year":"2002","journal-title":"Neurol. Res."},{"key":"10.1016\/j.nbd.2003.10.003_BIB78","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.0901-9928.2000.870305.x","article-title":"Copper, ceruloplasmin and superoxide dismutase (SOD) in amyotrophic lateral sclerosis","volume":"87","author":"Torsdottir","year":"2000","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB79","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0014-2999(01)01537-0","article-title":"Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2)","volume":"434","author":"Uberti","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nbd.2003.10.003_BIB80","first-page":"82","article-title":"The REAL-PET Study: slower progression in early Parkinson's disease treated with ropinirole compared with l-dopa","volume":"58","author":"Whone","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2003.10.003_BIB81","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0168-0102(02)00040-8","article-title":"The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals","volume":"43","author":"Yoshioka","year":"2002","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.nbd.2003.10.003_BIB82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/mds.870120105","article-title":"Levodopa induces apoptosis in cultured neuronal cells\u2014A possible accelerator of nigrostriatal degeneration in Parkinson's disease?","volume":"12","author":"Ziv","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2003.10.003_BIB83","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0024-3205(99)00062-4","article-title":"Neuroprotection by pramipexole against dopa","volume":"64","author":"Zou","year":"1999","journal-title":"Life Sci."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996103002067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996103002067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T16:52:15Z","timestamp":1623603135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996103002067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0969996103002067"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2003.10.003","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}